

Understanding fertility in women with chronic kidney disease

Submission date 26/07/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/09/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 28/09/2021	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Chronic kidney disease (CKD) is a long-term condition where the kidneys don't work as well as they should. Rates of CKD continue to rise in women of reproductive age, with 15% of patients less than 50 years old. This study aims to investigate how CKD affects the reproductive system, ovarian reserve (the number and quality of eggs) and inflammation. It also aims to investigate if increasing the intensity of dialysis improves fertility.

Who can participate?

Women aged 18-49 years with chronic kidney disease, or women between 18-49 years old with no medical history and no active or previous disease/treatment which could have affected their fertility.

What does the study involve?

The study will involve a minimum of one and a maximum of three visits. At each visit blood samples will be taken and a transvaginal scan will be carried out.

What are the possible benefits and risks of participating?

Participation will help the researchers to improve the care for women with kidney disease who have fertility problems. A fertility specialist will contact participants to give them their results, explain what they mean and how best to act on them if there is a problem. Their GP will be informed of any findings and if they need emotional support counsellors will be available as part of the study. There are no risks of taking part. The transvaginal ultrasound scan is safe and has no significant risks associated with it. Occasionally there is minimal discomfort during the scan but participants' wellbeing will be the upmost priority during the scan.

Where is the study run from?

King's Fertility, London (UK)

When is the study starting and how long is it expected to run for?

March 2000 to April 2023

Who is funding the study?
The Fetal Medicine Foundation (UK)

Who is the main contact?
Mahua Bhaduri
mahua.bhaduri@kingsfertility.co.uk

Contact information

Type(s)
Scientific

Contact name
Dr Mahua Bhaduri

Contact details
King's Fertility
First Floor
The Fetal Medicine Research Institute
16-20 Windsor Walk
London
United Kingdom
SE5 8BB
+44 (0)7792732092
Mahua.bhaduri@kingsfertility.co.uk

Additional identifiers

Integrated Research Application System (IRAS)
285546

Central Portfolio Management System (CPMS)
49608

Study information

Scientific Title
Fertility Evaluation in ReNal disease (FERN)

Acronym
FERN

Study objectives

1. Patients with chronic kidney disease (CKD) will have reduced ovarian reserve compared to healthy controls. This will be demonstrated by blood markers and a transvaginal scan
2. Female CKD patients will have dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis
3. Inflammatory markers in CKD women will be higher than normal controls

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/07/2021, London - Hampstead Research Ethics Committee (Ground Floor, Temple Quay, House 2, The Square, Bristol, BS1 6PN, UK; +44 (0)207 104 8345, +44 (0)207 104 8328; hampstead.rec@hra.nhs.uk), REC ref: 21/PR/0754

Study design

Observational; Design type: Cross-sectional

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Chronic kidney disease

Interventions

Study design: Multi-centre prospective observational cohort with blood sample collection and transvaginal ultrasound.

Setting: specialist renal clinics in the UK

Study duration per participant: Up to 6 months

Patients will be contacted and asked to fill in a patient questionnaire and sign patient consent forms.

Patients who have CKD and are not starting intensive haemodialysis will have at least one visit and a maximum of three visits with blood tests and a transvaginal scan at King's Fertility.

Patients who will be starting on haemodialysis will have three visits/sample collection times: prior to starting HD treatment, at 3 months of treatment and at 6 months. They will be also offered a transvaginal scan at each visit at King's Fertility.

All patients will be asked to fill out a validated questionnaire on how fertility impacts their quality of life.

Intervention Type

Other

Primary outcome(s)

1. Fertility assessed using blood markers (AMH, oestradiol, FSH, LH, progesterone, testosterone) and transvaginal ultrasound scan at baseline, 3 months and 6 months

Key secondary outcome(s)

1. The relationship of infertility, chronic kidney disease and chronic inflammation investigated using blood markers (O-link inflammatory panel) at baseline, 3 months and 6 months
2. Quality of life measured by a qualitative survey at baseline

Completion date

01/04/2023

Eligibility**Key inclusion criteria**

Study group:

1. Women with CKD Stages 1-5 including those with renal transplants and on dialysis
2. ≥ 18 years old but ≤ 49 years old
3. Willing and able to provide written informed consent

Control group:

1. Women aged 18-49 years
2. Male factor infertility
3. Willing and able to provide written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

49 years

Sex

Female

Key exclusion criteria

Study group:

1. Pregnant patients or those who are currently breastfeeding
2. Patient who have active or previous disease/treatment which could have affected their ovarian reserve i.e. chemotherapy, radiotherapy, ovarian surgery
3. Patients who require a translator

Control group:

1. Patients who have active or previous disease/treatment which could have affected their fertility
2. Patients who have female factor infertility, i.e. tubal factor, anovulatory disorders, endometriosis, fibroids, low ovarian reserve
3. Patients who have a known medical condition
4. Patient who require a translator

Date of first enrolment

01/08/2021

Date of final enrolment

01/10/2022

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

King's College Hospital

Denmark Hill

London

United Kingdom

SE5 9RS

Study participating centre

Leicester Royal Infirmary

Infirmary Square

Leicester

United Kingdom

LE1 5WW

Study participating centre

Royal London Hospital

Renal Department

Whitechapel Rd

Whitechapel

United Kingdom

E1 1FR

Study participating centre

NHS Nottingham North and East CCG

Gedling Civic Centre

Arnot Hill Park

Arnold

Nottingham

United Kingdom

NG5 0TE

Study participating centre**St Mary's Hospital**

The Bays
South Wharf Road
London
United Kingdom
W2 1BL

Study participating centre**St Thomas' Hospital**

Westminster Bridge Road
London
United Kingdom
SE1 7EH

Sponsor information**Organisation**

King's College Hospital NHS Foundation Trust

ROR

<https://ror.org/01n0k5m85>

Funder(s)**Funder type**

Charity

Funder Name

Fetal Medicine Foundation

Alternative Name(s)

FMF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	version 2.0	21/06/2021	04/08/2021	No	Yes
Participant information sheet	PIS for control group version 2.0	21/06/2021	04/08/2021	No	Yes